• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

EU Regulation On Identifier For Medical Products Published

09/02/2016 by Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

By Catherine Saez

An anti-counterfeiting regulation on a unique identifier for medical products to ensure their authenticity was published today in the European Union.

The European Commission Delegated Regulation EU 2016/161 [pdf] will allow for medicinal products to be verified and individual packs to be identified, according to the European Commission. It was adopted on 2 October 2015, and will apply as of 9 February 2019.

According to EUR-Lex, which provides information on European Union law, delegated acts mean that “the EU legislator (generally, the European Parliament and the Council)” can delegate to the Commission “the power to adopt non-legislative acts of general application that supplement or amend certain non-essential elements of a legislative act.”

According to the regulation, the manufacturer “shall place on the packaging of a medicinal product a unique identifier,” which complies with a number of technical specifications, such as the batch number, the expiry date, and a code allowing the identification of at least the name, the common name, the pharmaceutical form, the strength, the pack size and the pack type of the medicinal product.

The unique identifier “shall be a sequence of numeric or alphanumeric characters that is unique to a given pack of a medicinal product,” the regulation states.

The measure is aimed at “falsified” medical products, those presented as something they are not. “Counterfeit” medical products typically refer to trademark violations.

The measure was applauded by the European Generic and Biosimilar Medicines Association (EGA) as a major step in the fight against counterfeit medicines.

The EGA said it will work to ensure the national implementation of an “interoperable, pan-European repositories system, called the European Medicines Verification blueprint System,” with other stakeholders, such as the European Federation of Pharmaceutical Industries and Associations, the European Association of Euro Pharmaceutical Companies, the European Healthcare Distribution Association, and the Pharmaceutical Group of the European Union.

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"EU Regulation On Identifier For Medical Products Published" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Enforcement, English, Europe, Health & IP, Regional Policy, Trademarks/Geographical Indications/Domains

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2025 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.